BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kanno, M.
Right arrow Articles by Masuda, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kanno, M.
Right arrow Articles by Masuda, K.
Br J Ophthalmol 2000;84:293-299 ( March )

Effects of topical nipradilol, a beta  blocking agent with alpha  blocking and nitroglycerin-like activities, on intraocular pressure and aqueous dynamics in humans

Mikiko Kannoa, Makoto Araiea, Hiroshi Koibuchib, Kanjiro Masudaa

a Department Opthalmology, University of Tokyo School of Medicine, Japan, b Section of Ophthalmology, JR Tokyo General Hospital, Japan

Correspondence to: Makoto Araie, Department of Ophthalmology, University of Tokyo School of Medicine, 7-3-1 Hongo, Bunkyou-ku, Tokyo 113, Japan

Accepted for publication 1 October 1999

AIMS---To study the effects of topical nipradilol, a non-selective beta  blocker with alpha  blocking and nitroglycerin-like activities, on intraocular pressure (IOP) and aqueous humour dynamics in normal humans and in patients with ocular hypertension.
METHODS---Nipradilol (0.06%, 0.125%, 0.25%, 0.5%) was applied to normal volunteers (n = 12) to test for IOP lowering effects. In a second group of normal volunteers (n = 11), nipradilol (0.125% and 0.25%) and timolol (0.5%) were compared for IOP lowering effects. After a single administration of 0.25% nipradilol, IOP, flare intensity in the anterior chamber, aqueous flow, uveoscleral outflow, tonographic outflow facility, and episcleral venous pressure were either directly measured or mathematically calculated. Topical nipradilol (0.25%) was administered to 24 patients with ocular hypertension twice daily for 8 weeks.
RESULTS---Administration of 0.25% nipradilol decreased IOP with a maximum reduction of 4.2 mm Hg lasting 12 hours. A single instillation of both 0.25% nipradilol and 0.5% timolol reduced the IOP in normotensive human subjects to the same degree. A single instillation of 0.25% nipradilol decreased the aqueous flow rate in the treated eye by 20%. Nipradilol produced no significant effect in tonographic outflow facility or episcleral venous pressure, but uveoscleral outflow was increased. In patients with ocular hypertension, twice daily instillation of 0.25% nipradilol decreased IOP without tachyphylaxis for the 8 week test period.
CONCLUSION---Topical nipradilol (0.25%) reduced IOP by decreasing the aqueous flow rate and probably also by increasing uveoscleral outflow. Nipradilol should be further investigated as a new antiglaucoma drug.


© 2000 by British Journal of Ophthalmology



This article has been cited by other articles:


Home page
Arch OphthalmolHome page
T. V. Johnson, S. Fan, C. B. Camras, and C. B. Toris
Aqueous Humor Dynamics in Exfoliation Syndrome
Arch Ophthalmol, July 1, 2008; 126(7): 914 - 920.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
K. Mizuno, T. Koide, N. Saito, M. Fujii, M. Nagahara, A. Tomidokoro, Y. Tamaki, and M. Araie
Topical Nipradilol: Effects on Optic Nerve Head Circulation in Humans and Periocular Distribution in Monkeys
Invest. Ophthalmol. Vis. Sci., October 1, 2002; 43(10): 3243 - 3250.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
K. Mizuno, T. Koide, M. Yoshimura, and M. Araie
Neuroprotective Effect and Intraocular Penetration of Nipradilol, a {beta}-Blocker with Nitric Oxide Donative Action
Invest. Ophthalmol. Vis. Sci., March 1, 2001; 42(3): 688 - 694.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2000 by the BMJ Publishing Group Ltd.